Tag: TMVI
TMVI is a “reproducible and reliable” tool for eliminating mitral regurgitation
Findings of the CHOICE MI registry show that transcatheter mitral valve implantation (TMVI) is a...
Approval of Tendyne TMVI device means physicians now have a portfolio of options for treating mitral regurgitation
Abbott made history in January when it became the first company in the world to receive market a...
Abbott becomes first company in world to have transcatheter mitral implantation device on market
The Tendyne transcatheter mitral valve implantation (TMVI) system (Abbott) has received the CE mark,...
TMVI with Tiara valve may be safe and feasible for patients with prior aortic valve replacement
A new study indicates that transcatheter mitral valve implantation (TMVI) with the Tiara valve (...
ESC 2018: TMVI associated with “excellent outcomes” for valve-in-valve procedures
New results from the TMVR (Transcatheter mitral valve replacement) Registry show that patients w...
PRECLUDE study of Caisson TMVI system concludes
LivaNova has announced the conclusion of the PRELUDE feasibility study for its Caisson transcatheter...
Abbott launches trial of its Tendyne transcatheter mitral valve implantation device
Abbott has initiated a pivotal clinical study in the USA of its Tendyne transcatheter mitral val...
TVT 2018: Tiara TMVI device featured in live case
Neovasc announced that its Tiara transcatheter mitral valve implantation (TMVI) device was featu...
TMVI in inoperable patients is feasible but mortality high at one year
One-year outcome data for transcatheter mitral valve implantation (TMVI), in inoperable patients...
ICI 2017: Novel transcatheter mitral valve wins Best Technology Parade Presentation
4C Medical Technologies has won the Best Technology Parade Presentation award—at the 2017 Innovatio...
TCT 2017: TMVI in mitral ring is a reasonable alternative for high-risk patients
Data from the MITRAL (Mitral Implantation of Transcatheter valves) study indicate that transepta...
TCT 2017: Two studies support feasibility of transcatheter mitral valve implantation
Early experiences with two transcatheter mitral valve implantation (TMVI) devices—Intrepid (Medt...
First patient implanted with Intrepid TMVI device in APOLLO trial
The first patient in the APOLLO trial has undergone transcatheter mitral valve implantation (TMV...
Neovasc provides Tiara clinical update
Neovasc has provided an update on the study progress and clinical performance of the Tiara valve...
Novel mitral regurgitation therapy featured in Innovation Summit at Cardiovascular Innovations
4C Medical Technologies has announced that its medical device therapy for mitral regurgitation was f...
LivaNova acquires Caisson Interventional
LivaNova has announced it has acquired the remaining outstanding interests in Caisson Interventional...
Neovasc receives approval to launch European study of Tiara transcatheter mitral valve
Neovasc has received both regulatory and ethics committee approval to initiate the Tiara transca...
TCT 2016: Tiara TMVI device highlighted in presentations
Neovasc has announced today its notable presentations at the 2016 Transcatheter Cardiovascular T...
First-in-human implants of Caisson Interventional’s percutaneous mitral valve device performed
Caisson Interventional has announced the first successful human implants of its fully percutaneous, ...
TMVI: What we know
Transcatheter mitral valve implantation (TMVI) is being explored as an approach to managing patients...
FDA gives Neovasc go-ahead to add 40mm valve size to its TIARA-I clinical trial
The FDA has given Neovasc approval for participating physicians to treat patients with the c...
